Journal
FUTURE MEDICINAL CHEMISTRY
Volume 7, Issue 5, Pages 631-645Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc.15.13
Keywords
-
Categories
Funding
- Cancer Research UK
- Newcastle University
Ask authors/readers for more resources
Potent and selective small-molecule inhibitors of the p53-MDM2 interaction intended for the treatment of p53 wild-type tumors have been designed and optimized in a number of chemical series. This review details recent disclosures of compounds in advanced optimization and features key series that have given rise to clinical trial candidates. The structure-activity relationships for inhibitor classes are discussed with reference to x-ray structures, and common structural features are identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available